

Prima BioMed Ltd

CEO report to the Annual General Meeting of shareholders



*Matthew Lehman, CEO
15 November 2013
Radisson Blu Hotel, Sydney*

ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034



Notice: Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche Börse: YP1B.F). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima BioMed. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Cancer vaccines have great potential

For Drew Pardoll, Director of the Cancer Immunology Program in Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center:

. . . the real excitement lies with cancer vaccines. 'Their stock is very low right now, but they are going to come roaring back'

- Nature Reviews Drug Discovery, Vol 12, July 2013

The market for cancer immunotherapies is enormous



Citi Research
Equities

22 May 2013 | 52 pages

Drugs (Citi)
Europe | United Kingdom

Immunotherapy – The Beginning of the End for Cancer.

Transforming Cancer into Chronic Disease. Winners and Losers

- Immunotherapies—\$35bn potential/annum, will likely become the treatment backbone in up to 80% of cancers over the next 10 years compared with <3% today. The current explosion in all ongoing approaches (including checkpoint agents, vaccines and cell therapy) to utilise the immune system to seek and destroy cancer cells marks a watershed, analogous to the impact of HIV drugs transforming life expectancy in HIV,

■ Industry Overview



Andrew S Baum
+44-20-7986-4498
andrew.baum@citi.com


Mark Dainty, ACA
mark.dainty@citi.com



CVAC™ OVARIAN CANCER COMMERCIAL OPPORTUNITY

Compelling signal from CAN-003

Improving progression-free survival (PFS)



OSC	6/10	2/4	1/2	1/1	0/0
CVAC	3/10	2/6	0/4	1/3	0/0

Ovarian cancer – second remission

“80%-85% of patients tend to undergo second line therapy or maintenance therapy.

Therefore, a large group of patients seeking for second line is a significant sales driver for second line treatment drugs in the ovarian cancer market.”


Global Data’s 2011 report

“Paclitaxel (Ovarian Cancer) – Analysis and Forecasts to 2020”

Addressable market: 2nd remission ovarian

- Annual incidence of ovarian cancer in Australia & “major markets” (USA, Japan, UK, Germany, France, Italy, Spain) ~61,283 p.a. (2010)
- 70-75% diagnosed in late stage ~44,400 p.a.
- 70-80% of those platinum sensitive ~33,300 p.a.
- ***70-80% continue through second line ~25,000 p.a.***

CVac's place in ovarian cancer treatment



Comparative ovarian cancer deal



Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)

WHITEHOUSE STATION N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte's investigational companion diagnostic agent, etarfolatide (EC20).


"Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types," said Peter S. Kim, executive vice president and president Merck Research Laboratories. "This agreement underscores our strategy of building a portfolio of oncology therapeutics that employ a companion diagnostic to facilitate selection of those patients most likely to respond to treatment."

Under the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a \$120 million upfront payment and is eligible for milestone payments of up to \$880 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide for a total of six cancer indications. In addition, if vintafolide receives regulatory approval, Endocyte will receive an equal share of the profit in the United States (U.S.) as well as a double-digit percentage multiple on sales of the product in the rest of the world. Endocyte has



CVAC™ CLINICAL PATHWAY IN OVARIAN CANCER

Prima has compelling clinical data & a clear development path



*50% increase in median PFS
for ovarian cancer patients
in second remission*

*Extended time in remission
for the best responders to
CVac*

OSC	6/10	2/4	1/2	1/1	0/0
CVAC	3/10	2/6	0/4	1/3	0/0

Data from CVac CAN-003 protocol
PFS: progression free survival



What did we learn from CAN-003?

- Strong PFS signal in second remission epithelial ovarian cancer patient population
- Positive mucin 1-specific T cell response in CVac treated patients
- We have chosen Overall Survival (OS) as primary endpoint:
 - Clear regulatory (FDA) direction
 - Overall Survival was the endpoint for commercially approved cancer immunotherapies (Yervoy, Provenge)

Consequently, we modified our CAN-004 ovarian cancer protocol

- No new enrollment of 1st remission patients; patients currently enrolled will continue on CVac or placebo
- New patient group for analysis:
 - 210 patients in second remission
 - 1:1 randomization CVac vs. control group (observation only)
 - Primary endpoint = Overall Survival (OS)

Goal -> robust standard for proof of clinical concept



CVAC™ RESECTED PANCREATIC CANCER COMMERCIAL OPPORTUNITY & PILOT TRIAL

Addressable market: resected pancreatic cancer

- Annual incidence of pancreatic cancer in “major markets” (USA, Japan, UK, Germany, France, Italy, Spain) ~99,000 p.a.
- ~20% suitable for surgical resection ~20,000 p.a.
- 80-95% of those survive surgery **~17,000 p.a.**

CAN-301: A pilot pancreatic cancer trial


- 40 resected pancreatic cancer patients
- Single-arm pilot trial
- Endpoints:
 - Overall survival
 - Immune response
 - Safety

Goal -> data to add value to the CVac franchise & drive go/no-go decision on further clinical trials in pancreatic cancer




CVAC™ DEVELOPMENT OBJECTIVES

3 Priority Clinical Trials -> Objectives



Clinical Data Catalysts

Clinical Trial Protocols	Quarter (Calendar year basis)																	
	2013		2014				2015				2016				2017			
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
CAN-003	◇					×		○										
CAN-003X			×			×												
CAN-004 (1)					×		◇		×		+	◇	×				×	
CAN-004 (2)								×		◇		×		+	○			
CAN-301								×			◇	×	○	+				



*Exact timings dependent on regulatory reviews
& timing of clinical events (i.e disease progression and deaths)*



**STRONG FUNDAMENTALS
& EXCITING OUTLOOK**

Partners & advisors



Professor Ian Frazer AC, FRS, FAA, Chair of Scientific Advisory Board

CEO of Translational Research Institute; internationally renowned co-creator of technology for cervical cancer vaccines; cancer immunotherapy researcher at University of Queensland Diamantina Institute

Jonathan S. Berek, MD, MMS, Chair of Clinical Advisory Board

Established and directs the Stanford Women's Cancer Center, renowned expert in gynecologic oncology, especially the immunology and immunotherapy of gynecologic malignancies, group chair and PI of the Cooperative Ovarian Cancer Group, part of premiere international consortium, Gynecologic Cancer Intergroup



Holbrook Kohrt, MD, PhD, Senior Clinical Advisor

Assistant professor at Stanford University Medical Center; investigator on a number of NIH and industry sponsored oncology trials and has published extensively in the fields of cancer immunology and immunotherapy.



Budget for updated clinical plan

Key changes in the updated operational plan:

- 50% decrease in per-patient clinical costs due to protocol changes
- \$1.5 million p.a. reduction in manufacturing costs & internalization of expertise
- Continued management & reduction of corporate overhead expenses

An exciting future built from strong fundamentals

- Strong scientific collaborators and advisors
- Cash position \$31 million (30 Sept. 2013)
- Estimated 2+ years of cash reach
- Important CVac data catalysts in 2014, 2015, 2016
- Leadership position in the emerging field of cancer immunotherapy
- Evaluation of value accretive business development transactions